Company Description
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage.
Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
| Country | Canada |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Craig J. Mull |
Contact Details
Address: 2345 Argentia Road, Suite 100a Mississauga, A6 L5N 8K4 Ontario, Canada | |
| Phone | 905-602-5840 |
| Website | cipherpharma.com |
Stock Details
| Ticker Symbol | CPHRF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| CIK Code | 0001358575 |
| ISIN Number | CA17253X1050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig J. Mull | Interim Chief Executive Officer and Chairman of the Board |
| Bryan Jacobs | Chief Financial Officer |
| Dr. Diane Gajewczyk | Vice President of Scientific and Medical Affairs |
| Emilio Presti | Director of Sales and Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 22, 2017 | 15-12B/A | Filing |
| Jan 17, 2017 | 15-12B | Securities registration termination |
| Jan 3, 2017 | 6-K | Report of foreign issuer |
| Dec 21, 2016 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 21, 2016 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 21, 2016 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 9, 2016 | 25 | Filing |
| Dec 1, 2016 | 6-K | Report of foreign issuer |
| Nov 18, 2016 | 6-K | Report of foreign issuer |
| Nov 15, 2016 | 6-K | Report of foreign issuer |